Approval · Notice of Compliance 30282 · 2023
SEVOFLURANE: Notice of Compliance 30282
Issued March 9, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30282
- Date
- March 9, 2023
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Update to the Package Insert
- Canadian reference product
- SEVORANE AF (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SEVOFLURANE | Not yet assigned | — |
Medicinal ingredients
- SEVOFLURANE 99.97 PER